EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rethinking Oncologic Treatment Strategies with Interleukin-2

Brian Ko, Naoko Takebe iD, Omozusi Andrews, Monish Ram Makena iD, Alice P Chen iD

Cells · 2023

DOI: 10.3390/cells12091316 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Brian Ko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Treatment & Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-dose recombinant human IL-2 (rhIL-2, aldesleukin) emerged as an important treatment option for selected patients with metastatic melanoma and metastatic renal cell carcinoma, producing durable and long-lasting antitumor responses in a small fraction of patients and heralding the potential of cancer immunotherapy. However, the adoption of high-dose rhIL-2 has been restricted by its severe treatment-related adverse event (TRAE) profile, which necessitates highly experienced clinical providers familiar with rhIL-2 administration and readily accessible critical care medicine support. Given the comparatively wide-ranging successes of immune checkpoint inhibitors and chimeric antigen receptor T cell therapies, there have been concerted efforts to significantly improve the efficacy and toxicities of IL-2-based immunotherapeutic approaches. In this review, we highlight novel drug development strategies, including biochemical modifications and engineered IL-2 variants, to expand the narrow therapeutic window of IL-2 by leveraging downstream activation of the IL-2 receptor to selectively expand anti-tumor CD8-positive T cells and natural killer cells. These modified IL-2 cytokines improve single-agent activity in solid tumor malignancies beyond the established United States Food and Drug Administration (FDA) indications of metastatic melanoma and renal cell carcinoma, and may also be safer in rational combinations with established treatment modalities, including anti-PD-(L)1 and anti-CTLA-4 immunotherapy, chemotherapies, and targeted therapy approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsMelanomaHumansImmunotherapyInterleukin-2

Stichwörter der Autor:innen

IL-2cancercytokinesimmunotherapynemvaleukin alfa

Substanzen

Interleukin-2

Autor:innen und Institutionen

  • Division of Cancer Treatment & Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

ORCID-Profile: Naoko Takebe, Monish Ram Makena, Alice P Chen

Zitieren

APA

Ko, B., Takebe, N., Andrews, O., Makena, M. R., & Chen, A. P. (2023). Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells. https://doi.org/10.3390/cells12091316

Vancouver

Ko B, Takebe N, Andrews O, Makena MR, Chen AP. Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells. 2023. doi:10.3390/cells12091316

BibTeX
@article{Ko2023,
  author = {Ko, Brian and Takebe, Naoko and Andrews, Omozusi and Makena, Monish Ram and Chen, Alice P},
  title = {Rethinking Oncologic Treatment Strategies with Interleukin-2},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12091316}
}
Kostenlos starten →